AVROBIO, Inc. (AVRO) News

AVROBIO, Inc. (AVRO): $1.07

-0.04 (-3.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 404

in industry

Filter AVRO News Items

AVRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AVRO News Highlights

  • For AVRO, its 30 day story count is now at 20.
  • Over the past 20 days, the trend for AVRO's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
  • The most mentioned tickers in articles about AVRO are GENE, EAR and RARE.

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

2 Net Current Asset Value Stocks to Consider

Short-term investors could be interested in these businesses

Yahoo | February 21, 2022

AVROBIO (AVRO) Presents At AVROBIO WORLD Symposium 2022 Cystinosis

No summary available.

Seeking Alpha | February 14, 2022

Needham Thinks Avrobio’s Stock is Going to Recover

In a report released today, Gil Blum from Needham maintained a Buy rating on Avrobio (AVRO – Research Report), with a price target of $8.00. The company's shares closed last Wednesday at $1.65, close to its 52-week low of $1.62. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -35.1% and a 13.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83, representing a 216.8% upside.

Howard Kim on TipRanks | February 10, 2022

Mizuho Securities Sticks to Their Buy Rating for Avrobio (AVRO)

In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Avrobio (AVRO – Research Report), with a price target of $6.00. The company's shares closed last Wednesday at $1.65. According to TipRanks.com, Ear is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.9% and a 27.3% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and uniQure. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83.

Catie Powers on TipRanks | February 9, 2022

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Avrobio Inc''s (NASDAQ: AVRO ) gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. The data comes from a Phase 1/2 trial testing the safety and efficacy of AVR-RD-04 for cystinosis who had previously been given cysteamine, which is a standard treatment that reduces the buildup of cystine crystals in … Full story available on Benzinga.com

Benzinga | February 9, 2022

AVROBIO gains after interim data from cystinosis study for gene therapy

AVROBIO (AVRO) is trading ~11% higher in the pre-market on Wednesday after the company reported data from an ongoing Phase 1/2 clinical trial for AVR-RD-04 in adults…

Seeking Alpha | February 9, 2022

AVROBIO Inc. (NASDAQ: AVRO) Is Becoming An Interest-Losing Stock With A -2.56% Decline

In the latest trading session, 5.01 million AVROBIO Inc. (NASDAQ:AVRO) shares changed hands as the company’s beta touched 1.62. With the company’s most recent per share price at $1.72 changed hands at -$0.04 or -2.56% at last look, the market valuation stands at $74.69M. AVRO’s current price is a discount, trading about -1058.14% off its … AVROBIO Inc. (NASDAQ: AVRO) Is Becoming An Interest-Losing Stock With A -2.56% Decline Read More »

Marketing Sentinel | February 9, 2022

AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

CAMBRIDGE, Mass., February 09, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 18th Annual WORLDSymposium™ in San Diego.

Yahoo | February 9, 2022

AVROBIO Inc. (AVRO) Reprioritizes Pipeline Programs, Presentation - Slideshow

The following slide deck was published by AVROBIO, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 7, 2022

Mizuho Securities Thinks Avrobio’s Stock is Going to Recover

Mizuho Securities analyst Uy Ear maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price target of $6.00. The company's shares closed last Friday at $1.81, close to its 52-week low of $1.66. According to TipRanks.com, Ear is ranked 0 out of 5 stars with an average return of -22.3% and a 0.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and uniQure. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83.

Christine Brown on TipRanks | February 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4532 seconds.